Drug
Abbv 295
Abbv 295: highest development phase Phase 1, developed by AbbVie. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- AbbVie
Trials
| Drug | Phase | Indication |
|---|---|---|
| ABBV-295 NCT07514260 | Phase 1 | |
| ABBV-295 NCT07291232 | Phase 1 | Obesity |
Latest
No recent events.
Follow Abbv 295 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.